A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Ziyi Hu; Tingting Zhou; Fangrong Wu; Fan Lin

doi:10.3791/62312

Dziennik

/

Badania Nad Rakiem

/

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

JoVE Journal
Badania Nad Rakiem

Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.

JoVE Journal Badania Nad Rakiem

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

2,740 Views

•

05:29 min

•

March 28, 2021

DOI:

10.3791/62312-v

DOI:

10.3791/62312-v

•

05:29 min

March 28, 2021

•

1 Views

Ziyi Hu*¹, Tingting Zhou*¹, Fangrong Wu¹, Fan Lin^1,2

¹Department of Cell Biology, School of Basic Medical Sciences,Nanjing Medical University, ²Institute for Brain Tumors & Key Laboratory of Rare Metabolic Diseases,Nanjing Medical University; Nanjing Medical University Affiliated Cancer Hospital; Key Laboratory of Human Functional Genomics of Jiangsu Province

Transkrypcja

Podsumowanie

The glioma stem cells (GSCs) are a small fraction of cancer cells which play essential roles in tumor initiation, angiogenesis, and drug resistance in glioblastoma (GBM), the most prevalent and devastating primary brain tumor. The presence of GSCs makes the GBM very refractory to most of individual targeted agents, so high-throughput screening methods are required to identify potential effective combination therapeutics. The protocol describes a simple workflow to enable rapid screening for potential combination therapy with synergistic interaction. The general steps of this workflow consist of establishing luciferase-tagged GSCs, preparing matrigel coated plates, combination drug screening, analyzing, and validating the results.